Three Signals Converge on Eli Lilly

Why this matters: Three distinct ORTEX data streams—short interest, cost to borrow, and options sentiment—have simultaneously shifted on LLY in the past week. The convergence comes six days before the pharmaceutical giant reports Q1 2026 earnings.

Converging signals

Short interest climbed 1.5% day-over-day to 7.22 million shares on April 23, extending a recent uptick. The metric rose 1.2% over the past week, though it remains down 5.5% from a month ago. Short interest now stands at just 0.81% of free float, a modest level for a stock of this size.

Cost to borrow jumped 80% week-over-week to 0.38% APR. The sharp increase signals tighter availability of shares for new short positions. CTB peaked at 0.47% on April 17 before pulling back slightly. The metric is down 16% from a month ago but has doubled since mid-April.

The put/call ratio dropped to 1.06 on April 23, down 11% from the 20-day average of 1.19. The shift sits 2.2 standard deviations below recent norms, indicating a pronounced move toward call buying. Traders are positioning more bullishly ahead of the April 30 earnings event.

Corroborating context

Utilization sits at 39%, up from 37% a week ago and well above the March lows near 18%. The rise in utilization aligns with the cost-to-borrow spike, confirming tighter lending conditions. ORTEX's short score for LLY stands at 29.3, in the lower third of stocks tracked—consistent with the modest short interest level.

Data summary

• Short interest: 7.22M shares (0.81% of float), up 1.2% week-over-week
• Cost to borrow: 0.38% APR, up 80% from 0.21% on April 16
• Put/call ratio: 1.06, down from 1.19 average, 2.2 std devs below norm
• Utilization: 39%, up from 37% last week
• Next earnings: April 30 at 2:00 PM UTC
• Stock price: $917.65, up 1.5% over the past week

This is not financial advice. ORTEX data may contain inaccuracies.